Current Report Filing (8-k)

Date : 09/09/2019 @ 9:16PM
Source : Edgar (US Regulatory)
Stock : Respirerx Pharmaceuticals Inc. (QB) (RSPI)
Quote : 0.095  0.005 (5.56%) @ 4:31PM

Current Report Filing (8-k)

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

 

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 9, 2019

 

RESPIRERX PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

Delaware   1-16467   33-0303583
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (I.R.S Employer
Identification No.)

 

126 Valley Road, Suite C

Glen Rock, New Jersey

  07452
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (201) 444-4947

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

 

 

 
 

 

Item 7.01 Regulation FD Disclosure

 

On September 9, 2019, RespireRx Pharmaceuticals Inc. (the “Company”) announced that the Company’s Executive Chairman, Interim Chief Executive Officer, Interim President and Chief Scientific Officer, Arnold S. Lippa, Ph.D., and its Senior Vice President, Chief Financial Officer, Treasurer and Secretary, Jeff E. Margolis, each will be participating as a workshop leader and panel member, respectively at the 2nd Annual International Cannabinoid Derived Pharmaceuticals Summit at the Aloft Boston Seaport District in Boston, Massachusetts. Dr. Lippa is scheduled to participate as a workshop leader at 1:00 p.m. Eastern Time on Tuesday, September 10, 2019, and Mr. Margolis is scheduled to participate as a panel member at 5:30 p.m. Eastern Time on Wednesday, September 11, 2019.

 

The press release announcing Dr. Lippa’s and Mr. Margolis’s participation in the conference is attached as Exhibit 99.1, which is being furnished and not filed pursuant to Item 7.01 of Form 8-K

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits.

 

A list of exhibits that are furnished and filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere in this document, and is incorporated herein by reference.

 

 
 

 

EXHIBIT INDEX

 

Exhibit
Number
  Exhibit Description
99.1   Press Release dated September 9, 2019*

 

* Furnished herewith.

 

 
 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: September 9, 2019

RESPIRERX PHARMACEUTICALS INC.
     
  By: /s/ Jeff E. Margolis                             
   

Jeff E. Margolis

Senior Vice President, Chief Financial Officer, Treasurer and Secretary

 

 
 

RespireRx Pharmaceuticals Inc. (USOTC:RSPI)
Historical Stock Chart

1 Year : From Jan 2019 to Jan 2020

Click Here for more RespireRx Pharmaceuticals Inc. Charts.

RespireRx Pharmaceuticals Inc. (USOTC:RSPI)
Intraday Stock Chart

Today : Wednesday 29 January 2020

Click Here for more RespireRx Pharmaceuticals Inc. Charts.

Latest RSPI Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.